Abstract
The introduction of "new drugs" in the treatment of multiple myeloma (MM) significantly improved the prognosis of patients in the last 20 yeras. One of the most hopeful representatives of the new generation is daratumumab.
It is a human anti-CD38 monoclonal antibody that binds with high affinity to CD38-expressing malignant cells and induces their death by various machanisms. Combined standard regimens with daratumumab represent the most effective treatment in patients with refractory/relapsing MM yet.
Daratumumab is a milestone in MM therapy similar to rituximab in lymphomas. Based on the results of POLLUX and CASTOR, it is assumed that it could become a key component of healing combinations for patients with refractory/relapsing disease and at least one previous treatment line in the near future.